Skip to content

Study · Non-randomized trial · n = 69 · 2026

4 results

Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide.

Wendel D, Wales PW, Kocoshis S, Venick R, Carter B, Cohran V, Matthews C, Raphael BP, Robinson I, Hill S

Journal of pediatric gastroenterology and nutrition19 Mar 2026Cited by 1 (Europe PMC)

PMID41858082 (opens in a new tab)PMCIDPMC13342760 (opens in a new tab)DOI10.1002/jpn3.70358 (opens in a new tab)PepBankPUB-41858082
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with SBS-IF receiving teduglutide, mean patient-reported PedsQL was 75.0 (SD 16.2).

    In plain wordsChildren with SBS-IF receiving teduglutide had a mean quality-of-life score of 75.0.

    Peptide
    Teduglutide
    Outcome
    Not applicablePatient-reported PedsQL score
    Study

    n = 69

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Measurements

    Mean PedsQL
    75 points
    reported result
    SD
    16.2 points
    reported result

    Source sentences

    Summary
    In pediatric patients with SBS-IF receiving teduglutide (n = 69), the total mean (standard deviation) patient-reported PedsQL score was 75.0 (16.2).
    2 context sentences
    Summary · context
    Two long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module.
    Summary · context
    Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children receiving teduglutide, mean PedsQL scores remained stable over 96 weeks regardless of enteral autonomy.

    In plain wordsIn children receiving teduglutide, quality-of-life scores stayed stable over 96 weeks, regardless of enteral autonomy.

    Peptide
    Teduglutide
    Outcome
    No significant changePedsQL over 96 weeks
    Study

    n = 69

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mean PedsQL scores remained stable over 96 weeks regardless of patients achieving enteral autonomy.
    2 context sentences
    Summary · context
    Two long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module.
    Summary · context
    Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study.
  3. 03HumanObservational studyEfficacy outcome

    In children receiving teduglutide, higher baseline stool frequency predicted higher patient-reported HRQoL (p = 0.03).

    In plain wordsIn children receiving teduglutide, higher baseline stool frequency was linked to higher reported quality of life.

    Peptide
    Teduglutide
    Outcome
    IncreaseBaseline stool frequency and patient-reported HRQoL
    Study

    n = 69

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Measurements

    P value
    0.03 unitless
    baseline stools per day as predictor of patient-reported HRQoL

    Source sentences

    Summary
    Higher mean number of stools per day at LTE study baseline (p = 0.03) predicted increased patient-reported HRQoL.
    2 context sentences
    Summary · context
    Two long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module.
    Summary · context
    Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study.
  4. 04HumanObservational studyEfficacy outcome

    In children with SBS-IF, longer teduglutide exposure predicted higher caregiver-proxy HRQoL (p = 0.047).

    In plain wordsIn children with SBS-IF, longer teduglutide exposure was linked to higher caregiver-reported quality of life.

    Peptide
    Teduglutide
    Outcome
    IncreaseExposure duration and caregiver-proxy HRQoL
    Study

    n = 69

    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Longer teduglutide exposure (p = 0.047), increasing length of remnant small intestine (p = 0.034), and older age (p = 0.026) predicted higher caregiver-proxy-reported HRQoL.
    2 context sentences
    Summary · context
    Two long-term extension (LTE) studies (NCT02949362, NCT02954458) assessed HRQoL over 96 weeks using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL Family Impact Module.
    Summary · context
    Patients included in this analysis received teduglutide in one of three randomized Phase 3 parent studies and the respective LTE study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02954458

Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)

Shiren = 619 Jan 2017 to 5 Nov 2020

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 28 Mar 2025
CompletedPhase 3Results postedNCT02949362

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

Shiren = 299 Dec 2016 to 14 Jul 2020

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 19 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.